(Reuters) – Regeneron Pharmaceuticals and Sanofi will cut the net price of their expensive cholesterol drug for Express Scripts customers in exchange for greater patient access, with some savings to be shared with consumers, the companies said on Tuesday.
Boehringer Ingelheim has expanded access to its digital adherence programme that helps COPD patients take their medicines as
The post Boehringer Ingelheim rolls-out COPD digital adherence programme appeared first on Pharmaphorum. https://pharmaphorum.com/news/boehringer-copd-digital-adherence/
The price lists may still be confusing to consumers, though, because standard rates are like list prices and don’t reflect what insurers and government programs pay. “Given the inherent complexity of hospital billing, making prices easy to understand is clearly a lot easier said than done,” Shawn Gremminger, of Families USA. https://khn.org/morning-breakout/hospitals-to-be-required-to-post-prices-online-as-part-of-cms-push-to-increase-transparency/
There is a growing trend in big pharma to talk up the potential for digital technology to revolutionise operations and Novartis is one of the companies that is most actively announcing steps to explore this possibility.
In August of last year, the company announced a new position, Chief Digital Officer, and the man to take the position, in Bertrand Bodson.
read more http://www.pharmafile.com/news/517158/novartis-forges-forward-digital-pharma-focalview-app
US regulatory advisors are backing approval of the lower dose form of Eli Lilly and Incyte’s once-daily JAK inhibitor baricitinib as treatment for rheumatoid arthritis (RA). http://www.pharmatimes.com/news/fda_advisors_back_lillyincytes_rheumatoid_arthritis_drug_1233030
The integration of roles in the health system should theoretically result in better coordination of care and outcomes for patients. … http://www.pm360online.com/how-pharma-can-help-patients-feel-less-overwhelmed-when-dealing-with-payers/
Sandoz, a division of Novartis, and Pear Therapeutics have agreed to jointly commercialize and continue development of novel prescription digital therapeutics designed to treat disease and improve clinical outcomes for patients. http://drugdiscovery.pharmaceutical-business-review.com/news/sandoz-pear-to-develop-digital-therapeutics-for-substance-use-disorder-190418-6121611
It’s the first screening device the FDA has authorized that doesn’t need a clinician’s interpretation to look for a particular condition. In other news, the agency also is going to relax its review of next-generation sequencing tests. https://khn.org/morning-breakout/software-that-uses-artificial-intelligence-to-screen-eyes-for-diabetes-damage-approved-by-fda/